AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.
NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, PhD, has been named the company’s CEO. Fibronostics is a global diagnostics company, providing non-invasive, algorithmic diagnostics and insights to detect and manage organ lesions caused […]
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD.
ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D).
Fibronostics_ADA-2021
EASL Poster: Noninvasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients.
2021_EASL_ePOSTER_Transition-to-Fibrosis-vf-submitted
